US Stock MarketDetailed Quotes
NGNE Neurogene
- 30.320
- -9.680-24.20%
Close Jun 18 16:00 ET
- 30.100
- -0.220-0.73%
Post 19:45 ET
393.56MMarket Cap-10706P/E (TTM)
39.990High29.690Low209.27KVolume38.710Open40.000Pre Close6.79MTurnover3.52%Turnover RatioLossP/E (Static)12.98MShares53.00052wk High2.30P/B180.44MFloat Cap12.20052wk Low--Dividend TTM5.95MShs Float1115.000Historical High--Div YieldTTM25.75%Amplitude7.500Historical Low32.452Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Neurogene Stock Forum
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet